Key result
Hypertrophic cardiomyopathy remains widely underdiagnosed despite an estimated prevalence of up to ~0.8%.
Hypertrophic cardiomyopathy remains an underdiagnosed condition with a need for expanded access to novel therapies like myosin inhibitors, especially in pediatric populations.
Raises awareness of pediatric HCM underdiagnosis; leaves open questions on myosin inhibitor trials and access.
Hypertrophic cardiomyopathy (HCM) is an inheritable cardiac disease characterized by the hypertrophy of the myocardial segments. HCM is the leading cause of sudden cardiac death in young athletic adults in the United States. While the prevalence rate of HCM is 0.2-0.8%, it is widely underdiagnosed. Left ventricle hypertrophy is most observed, but other myocardial segments are also susceptible to hypertrophy. These include anterolateral wall, apex, mid-ventricular, isolated basal septa, and asymmetric interventricular septal hypertrophy. Outcomes in HCM have improved over the years but continue to require access to better therapies in young children, who currently do not have access to myosin inhibitors.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy is an inheritable cardiac disease with a prevalence of 0.2-0.8% that remains widely underdiagnosed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: